icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
6shmH7Hkr2uq56Xp
Listen
